Cargando…
Safety and Efficacy of Risankizumab and Infliximab in the Treatment of Plaque Psoriasis: Results From a Direct and Indirect Meta-Analysis
The objective of our study was to compare a potent drug of the anti-TNF class family, infliximab, with a potent drug of the IL-inhibitors family, risankizumab, in terms of efficacy and safety endpoints. Online databases were searched for relevant placebo-controlled, randomized trials. The following...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315299/ https://www.ncbi.nlm.nih.gov/pubmed/34336456 http://dx.doi.org/10.7759/cureus.15963 |